CTOs on the Move

Senseonics

www.senseonics.com

 
Senseonics, Incorporated (formerly Sensors for Medicine and Science, Inc.) is developing transformative glucose monitoring products that are intended to enable people with diabetes to confidently live their lives with ease. Utilizing breakthrough fluorescence sensing technology, the Senseonics Continuous Glucose Monitoring System is being designed to be the first fully implantable continuous glucose monitoring system that is highly accurate and stable throughout its long sensor life.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.senseonics.com
  • 20451 Seneca Meadows Parkway
    Germantown, MD USA 20876
  • Phone: 301.515.7260

Executives

Name Title Contact Details

Similar Companies

Axion Pharmaceuticals

Axion Pharmaceuticals is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Synlogic

The Synlogic drug discovery engine is based on an engineering methodology that uses standardized and well-characterized interchangeable parts, as well as cutting-edge, logical gene-circuit control features. These unique and proprietary elements allow the scientific team to rapidly design, build and test synthetic life that leverage the microorganisms (bacteria and viruses) that live in and interact with the human body and transform them into programmable symbiotic living therapeutics that exhibit exquisite genetic control in response to pathophysiological signals. In a very short time, Synlogic has applied this platform to develop two lead programs in rare diseases that are advancing towards clinical development, as well as earlier programs in larger disease indications such as inflammation and metabolic diseases.

Hollister-Stier Laboratories

Hollister-Stier Laboratories is a Spokane, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

iCo Therapeutics

iCo Therapeutics Inc. is a Vancouver-based development company focused on in-licensing drugs with clinical history redosing or reformulating for new or expanded indications. iCo has exclusive worldwide rights to three products. iCo-007, a second generation antisense candidate licensed from Isis Pharmaceuticals, is currently in a Phase I trial in Diabetic Macular Edema patients with compelling early data. iCo-008 is a human monoclonal antibody targeting eotaxin-1 with Phase II clinical history, licensed from AstraZeneca/MedImmune. iCo-009 is a proprietary oral formulation of amphotericin B licensed from the University of British Columbia.

Lathrop

Lathrop is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.